Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2001-01-18 | Forward | 3:1 |
| 1999-12-21 | Forward | 2:1 |
Biogen Inc. develops therapies for neurological diseases, including multiple sclerosis, Alzheimer's, and neurodegenerative disorders, with a broad portfolio of biologics, biosimilars, and research collaborations.
Leqembi, an FDA-approved antibody therapy for Alzheimer's that removes amyloid beta plaques, is a key growth driver for Biogen's focus on neurological diseases and represents the company's shift toward innovative treatments.
Biogen announced its second-quarter 2025 financial results on July 31, 2025, reporting revenue and earnings that significantly beat analyst expectations. This strong performance, driven by the growth of new products like the Alzheimer's drug Leqembi, led the company to raise its full-year financial guidance, signaling confidence in its growth trajectory and resulting in a notable increase in its stock price.
In a major strategic realignment, Biogen initiated a significant restructuring of its research department, involving layoffs and a fundamental shift in its innovation model. The company is deliberately moving resources away from internal preclinical discovery to focus on acquiring or partnering on external opportunities, aiming to improve R&D productivity and build a new growth engine.
Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) is expected to report a slight third-quarter earnings per share beat at $2.14, against a consensus of $2.07, when it reports on October 28, says Jefferies. Revenue should be in line at $2.6 billion, with lower cost of goods sold and research and development expenses partly offset by higher selling, general and administrative costs.
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicin
Biogen said on Friday its experimental drug showed durable improvement in skin symptoms among patients with a type of autoimmune disease in a mid-stage study.
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated results, presented at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria, represent the longest dataset reported for litifilimab in CLE and further support its potential to achieve rapid and durable improvements in skin disease activity. In the study, participants treated with litifilimab in the double-blind, placebo-controlled period showed continued clinical improvements in skin disease activity through Week 52. Notably, participants who switched from placebo to litifilimab treatment at Week 24 experienced a rapid onset of treatment effect as early as four weeks.
Overall rating: B+
| PEER | PRICE | |
|---|---|---|
 LLY | $1152.80 | COMPARE |
 AZN | $158.13 | COMPARE |
 AMGN | $406.31 | COMPARE |
 PFE | $27.80 | COMPARE |
 VRTX | $504.43 | COMPARE |
 REGN | $737.77 | COMPARE |
 TEVA | $39.10 | COMPARE |
 WAT | $436.04 | COMPARE |
